BB Biotech的投资组合在2025年第二季度表现优于生物科技板块指数，主要得益于Revolution Medicines、Oruka和Relay Therapeutics的股价上涨。 随着公司向AI驱动的运营模式转型，其投资步伐加快，每季度新增10多项头寸，而历史同期仅为一到两项。 公司预计将于2025年完成其专有的AI运营系统，将所有投资和研究功能整合到一个统一的平台。 股价上涨1.5%至 ...

近日，《Fierce Biotech》发布了一份年度特殊报告，记录了今年以来全球生物科技领域的“阵亡名单”—— 截至11月1日，2025年共有16家生物科技企业正式关停，另有3家濒临破产，挣扎在生死边缘。 而就在该报告发布一周后，Arena ...

Biotech一级市场融资在今年3月迎来了久违的“小高峰”，总融资额超过了21亿美元。 这主要是由于两家明星公司分别获得了两笔大额融资：TYK2抑制剂同类最佳竞争者公司Alumis获得2.59亿美元C轮融资，以及Prometheus创始人再次创业成立的自免药物公司Mirador Therapeutics获得4亿美元A轮融资。

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, ...

So far in 2026, biotech deals amounted to $106 billion over 201 transactions, according to PitchBook data. That momentum in dealmaking comes despite an interest rate environment that has turned for ...

AbbVie stock rose early Friday after the drug giant easily beat third-quarter forecasts with the help of its biggest drug, Skyrizi.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

More biotech companies filed for bankruptcy in 2023 than any year since 2010, underscoring a brutal year defined by layoffs, company closures and pipeline reprioritizations, according to data from S&P ...

Even if unlucky startups continue to be sent to the biotech graveyard, there is hope that their science will survive the grave. (mtreasure/iStock/Getty Images Plus) That brighter outlook is also ...

The biotechnology industry's mission is to advance the well-being of life on earth through developments in technological processes that support advances in health of all forms. Biotech applications ...

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing ...